Clinical Trial

A Study To Characterize Mass Balance Of [14C] HDM1002 in Chinese Healthy Subjects

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated September 4, 2024 (before its estimated October 2024 completion). Its status may not reflect the trial's current state.
Summary
In this study, a single dose of \[14C\] radiolabelled HDM1002 will be administered orally. The main purpose of this study is to find out how much of HDM1002 and its metabolites pass from blood into urine and feces, and characterize the metabolic profile and routes of excretion of oral \[14C\] HDM002.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-08-26.
Status change: Not Yet Recruiting → Recruiting 2024-09-03
Trial Details
NCT Number NCT06576401
Lead Sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Conditions Healthy Adult Subject
Enrollment 10 participants
Start Date 2024-08-27
Primary Completion 2024-10 (estimated)
Study Completion 2024-12 (estimated)
Updated on ClinicalTrials.gov 2024-09-04